Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
Q3 2021 revenue of $15.1 million and Adjusted EBITDA of $6.9 million, up 15% and 53%, respectively, from Q3 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2021 financial results on Thursday, November 4, 2021. The Company will hold a conference call that...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in two...
Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary...
Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2021 financial results on Thursday, August 5, 2021. The Company will hold a conference call that...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...
Q1 2021 revenue of $14.3 million, Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million, up $0.4 million, $0.6 million and $1.8 million, respectively, from Q1 2020 Vascepa...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021. The Company will hold a conference call that same...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...
HLS Therapeutics Inc. regrets the adoption of a new regulation, published yesterday in the Gazette officielle du Québec, which limits access to a support program for new patients suffering from...
Dorval, le 1er avril 2021. — HLS Therapeutics Inc. déplore l’adoption d’un nouveau règlement, publié hier dans la Gazette officielle du Québec, qui aura des conséquences sur l’accès...
CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on March 26, 2021 Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes...
Fourth quarter revenue of $16.5 million, Adjusted EBITDA of $8.7 million and cash from operations of $5.8 million Produced strong Vascepa® prescription growth amid COVID-19 challenges: more than...
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%,...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2020 financial results by press release at 6:30 a.m. EST on Thursday, March 18, 2021....
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will participate in...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will be participating...
Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021, up from 50% in November 2020 Coverage effective for statin-treated patients...
Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1 Chinese Society of Cardiology updated Guidelines now include...